TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Mon, 07th Feb 2022 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Alphawave IP Group PLC - designs and licences chip technology - Teams with Intel Corp's Intel Foundry Services. Intel Foundry is a unit of Santa Clara, California-based Intel. It manufactures third-party chips. "By combining Intel's manufacturing and operational prowess with Alphawave IP's technology leadership in connectivity solutions, the partnership will enable some of the world's largest chip companies and hyperscalers to build the most advanced semiconductor devices in 2022 and beyond," Alphawave says.

----------

Cadence Minerals PLC - London-based investor in mineral resources - Says required contractual and regulatory documentation completed and filed at Amapa iron ore project, sealing process and ensuring Cadence now owns 20% of the Brazil-based project. Cadence notes Anglo American PLC, a previous owner, valued the asset at USD1.2 billion and impaired it at USD600 million back in its 2012 accounts.

----------

Oilex Ltd - Perth-based company focused on the development of natural gas assets - India's Ministry of Environment, Forest & Climate Change confirms decision to approve environmental clearance for Cambay field.

----------

Hunting PLC - London-based supplier to oil and gas industry - Refinances core borrowing facilities and enters into USD150 million asset based lending facility with Wells Fargo and HSBC. New facility has four-year term and replaces USD160 million revolving credit facility. "The ABL facility contains an accordion feature of up to a further USD50 million which is accessible subject to further credit approval from the relevant lenders, enabling the company to increase the total facility quantum to USD200 million," Hunting adds.

----------

Helium One Global Ltd - London-based exploration & development company - Begins electrical resistivity tomography at Rukwa asset. Survey will probe area identified from phase I and phase II 2D seismic surveys. Will also investigate "surface helium anomalies identified in recently completed multispectral satellite spectroscopy study".

----------

Wildcat Petroleum PLC - targeting investment opportunities in businesses and assets within the upstream sector of the petroleum industry, including the use of blockchain within the sector - Names PETRO-TEC as petroleum consultants. "PT will be able to devise, implement, run and evaluate appropriate field development projects alongside WCAT," company says.

----------

Insig AI PLC - London-based machine learning and data science firm which serves the asset management industry, formerly known as Catena Group PLC - Picked for PwC's Scale FinTech programme, aiming to give access to new opportunities within the accounting firm and its clients. "After an extensive selection process, Insig AI was one of only nine companies this year chosen from more than 700 applicants from around the world. Insig AI is also the only FinTech with ESG expertise on the programme," Insig says.

----------

Octopus Renewables Infrastructure Trust PLC - London-based investment company focused on renewable energy assets in Europe and Australia - Declares 1.25 pence per share dividend for fourth quarter ended December 31. Notes 2021 payout totals 5.0p per share, meeting target. For 2022, it eyes 5.24p payout, up 4.8%.

----------

ImmuPharma PLC - London-based drug discovery and development company - Says UK Medical & Health Products Regulatory Agency approves pharmacokinetic study Lupuzor in Lupus patients. "Volunteers have been selected and approved for inclusion in the PK study," company says. Vounteer dosing to begin on February 15 and study on track to deliver results by end of first quarter.

----------

Ondine Biomedical Inc - Vancouver, Canada-based life sciences company focused on photodisinfection-based therapies - Treats first patients in phase 2 of US Food & Drug Administration nasal photodisinfection exploratory trial. "The study will evaluate how effectively the treatment eradicates pathogens -Staphylococcus aureus - in the nose, and the occurrence of surgical site infections within 30 days of surgery," Ondine adds.

----------

By Eric Cunha; ericcunha@alliancenews.com